Kilitch Drugs (India) Share Price
NSE: KILITCH | Pharmaceuticals | Small Cap
Kilitch Drugs (India) Annualised Returns
Kilitch Drugs (India) Annualised Returns
Kilitch Drugs (India) Share Price Today
Kilitch Drugs (India) Share Price Today
As of 26 Oct 2026, Kilitch Drugs (India) share price is ₹202.2. The stock opened at ₹204 and had closed at ₹202.1 the previous day. During today’s trading session, Kilitch Drugs (India) share price moved between ₹196.10 and ₹211.61, with an average price for the day of ₹203.86. Over the last 52 weeks, the stock has recorded a low of ₹117.25 and a high of ₹267.90. In terms of performance, Kilitch Drugs (India) share price has increased by 32.9% over the past six months and has increased by 10.39% over the last year.
Kilitch Drugs (India) Stock Performance
Kilitch Drugs (India) Share Price Chart
Kilitch Drugs (India) Share Price Chart
Kilitch Drugs (India) Company background
Kilitch Drugs (India) Limited (KDIL), incorporated in May, 1992 is the one of the leading and fastest growing pharmaceutical companies in the world, manufacturing, supplying and marketing broad range of pharmaceutical formulations in the various dosage forms like Solid, Liquid and Parental across the globe. Its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms of creating safe pharmaceutical solutions.The Company went public in Feb.94 to set up a pharmaceutical formulation plant at Thane to manufacture pharmaceutical products in the form of tablets, capsules, liquid orals, ointments, creams and injectables. Even before the plant was commissioned, the company came out with a rights issue in Oct.95 to expand the capacity. Commercial production at the plant at Thane commenced in 1996. The company has two divisions O T C and ethical.A Pharmaceutical formulation plant at Sanaa Republic of Yemen was set up at a cost of Rs 15 crore by entering into an agreement with AlFath Trading Corporation. It also entered into an agreement with a Miami company for the export of their medicine to West Indies, south and central America.The company entered into a contract with one of the leading company in the Republic of Yemen which it had set up at a cost of Rs 2.5cr tanning unit, which was implemented in the year 199596. The company had set up a bulk drug unit at Patalganga, Maharashtra for producing raw materials for formulations. The company exports to Sudan, Yemen, middleeast, Miami and certain south American companies. KDIL started marketing a range of injectables from the factory on ethical basis. The company also introduced a new product clueplus, BonBon Gripe Water and Kilitch Balm.The Company launched a new product BENIN in the market in 2011. During the year 201112, the Company sold its business located at Paonta Sahib, Himachal Pradesh as a going concern on a slump sale basis along with transfer of services set forth in the Business Transfer Agreement (BTA). The undertaking was sold and transferred on 28th February 2012 after getting all the necessary clearances as indicated in the BTA. It retained its Name, Trademark (Kilitch) and all other properties and assets at Mumbai. It transferred certain products by entering into a Product Transfer Agreement (PTA) with Akorn India Pvt. Ltd. (AIPL) by which the right to manufacture certain products by the Company at Mumbai were sold to AIPL.The Company has set up a New Manufacturing Facility at Pen, Maharashtra in 2026.
Kilitch Drugs (India) Financial Highlights
For Q1 FY2026–2027, Kilitch Drugs (India)'s revenue reached ₹47.78 crore and profit touched at ₹2.91 crore. As of 26 October 2026, Kilitch Drugs (India)’s market capitalization reached at ₹707.06 crores. Shareholding as of 26 October 2026 shows promoters holding 63.8%, with FIIs at 0.1%, DIIs at 0.5%, and public at 35.6%.
Kilitch Drugs (India) Fundamental
Market Cap (in crs)
707.06
Face Value
10
Turnover (in lacs)
292.28
Key Metrics
Kilitch Drugs (India) Key Financials
View moreKilitch Drugs (India) Result Highlights
-
Kilitch Drugs (India) Ltd reported a 10.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 66.6%.
-
Its expenses for the quarter were up by 17.4% QoQ and 55.5% YoY.
-
The net profit decreased 34.8% QoQ and increased 222.4% YoY.
-
The earnings per share (EPS) of Kilitch Drugs (India) Ltd stood at 3.7 during Q3FY25.
Data Source: BSE, Company announcements
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.
Kilitch Drugs (India) Technical Analysis
Delivery & Volume
Delivery Volume %
Day
47.50%
Week
49.90%
Month
47.90%
Resistance & Support
Kilitch Drugs (India) Peer comparison
CompareIndex Name | Market Price |
|---|---|
178.47 -7.30 (-3.93%)▼ | |
76.63 -2.24 (-2.84%)▼ | |
627.45 -27.40 (-4.18%)▼ | |
126.22 -5.90 (-4.47%)▼ | |
128.43 -2.62 (-2.00%)▼ | |
491.50 -10.00 (-1.99%)▼ |
Kilitch Drugs (India) Latest News
Kilitch Drugs (India) Share Price FAQs
Kilitch Drugs (India) Ltd share price is ₹202.24 in NSE and ₹203.5 in BSE as on 23/10/2026.
Kilitch Drugs (India) Ltd share price in the past 1-year return was 9.55. The Kilitch Drugs (India) Ltd share hit a 1-year low of Rs. 117.25 and a 1-year high of Rs. 267.9.
The market cap of Kilitch Drugs (India) Ltd is Rs. 707.06 Cr. as of 23/10/2026.
The PE ratios of Kilitch Drugs (India) Ltd is 21.79 as of 23/10/2026.
The PB ratios of Kilitch Drugs (India) Ltd is 2.13 as of 23/10/2026
You can easily buy Kilitch Drugs (India) Ltd shares in Kotak Neo by opening a demat account and getting the KYC documents verified online.
The 52-week high and low of Kilitch Drugs (India) Ltd share price is ₹267.9 and ₹117.25 as of 23/10/2026.
Please be aware that Kilitch Drugs (India) Ltd stock prices are subject to continuous fluctuations due to various factors.